Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | Flap nuclease, putative | 0.0032 | 0.2612 | 0.8145 |
Onchocerca volvulus | Bile acid receptor homolog | 0.0007 | 0 | 0.5 |
Giardia lamblia | Flap structure-specific endonuclease | 0.0032 | 0.2612 | 1 |
Brugia malayi | XPG I-region family protein | 0.0011 | 0.0361 | 0.1382 |
Toxoplasma gondii | flap structure-specific endonuclease 1, putative | 0.0032 | 0.2612 | 0.8145 |
Echinococcus granulosus | DNA repair protein complementing XP G cells | 0.0036 | 0.3124 | 1 |
Trichomonas vaginalis | flap endonuclease-1, putative | 0.0036 | 0.3124 | 1 |
Brugia malayi | Flap endonuclease-1 | 0.0032 | 0.2612 | 1 |
Echinococcus granulosus | exonuclease 1 | 0.0011 | 0.0361 | 0.1156 |
Echinococcus granulosus | flap endonuclease GEN 1 | 0.0011 | 0.0361 | 0.1156 |
Plasmodium vivax | DNA repair protein RAD2, putative | 0.0036 | 0.3124 | 1 |
Echinococcus multilocularis | exonuclease 1 | 0.0011 | 0.0361 | 0.1156 |
Entamoeba histolytica | DNA-repair protein, putative | 0.0036 | 0.3124 | 1 |
Schistosoma mansoni | hypothetical protein | 0.005 | 0.4584 | 0.4584 |
Trypanosoma brucei | RNA helicase, putative | 0.01 | 1 | 1 |
Onchocerca volvulus | 0.0007 | 0 | 0.5 | |
Toxoplasma gondii | XPG N-terminal domain-containing protein | 0.0036 | 0.3124 | 1 |
Schistosoma mansoni | exonuclease | 0.0011 | 0.0361 | 0.0361 |
Plasmodium vivax | flap endonuclease 1, putative | 0.0032 | 0.2612 | 0.8145 |
Brugia malayi | XPG N-terminal domain containing protein | 0.0031 | 0.2519 | 0.9644 |
Schistosoma mansoni | flap endonuclease-1 | 0.0027 | 0.2069 | 0.2069 |
Schistosoma mansoni | xp-G/rad2 DNA repair endonuclease family | 0.0036 | 0.3124 | 0.3124 |
Echinococcus granulosus | flap endonuclease 1 | 0.0032 | 0.2612 | 0.836 |
Plasmodium falciparum | DNA repair protein RAD2, putative | 0.0036 | 0.3124 | 1 |
Trypanosoma brucei | flap endonuclease-1 (FEN-1), putative | 0.0032 | 0.2612 | 0.2335 |
Loa Loa (eye worm) | flap endonuclease-1 | 0.0032 | 0.2612 | 0.836 |
Onchocerca volvulus | Protein ultraspiracle homolog | 0.0007 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0036 | 0.3124 | 1 |
Echinococcus multilocularis | DNA repair protein complementing XP G cells | 0.0036 | 0.3124 | 1 |
Trypanosoma cruzi | flap endonuclease-1 (FEN-1), putative | 0.0032 | 0.2612 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0011 | 0.0361 | 0.1156 |
Onchocerca volvulus | Steroid hormone receptor family member cnr14 homolog | 0.0007 | 0 | 0.5 |
Schistosoma mansoni | xp-G/rad2 DNA repair endonuclease family member | 0.0011 | 0.0361 | 0.0361 |
Loa Loa (eye worm) | XPG I-region family protein | 0.0011 | 0.0361 | 0.1156 |
Echinococcus multilocularis | flap endonuclease 1 | 0.0032 | 0.2612 | 0.836 |
Trichomonas vaginalis | flap endonuclease-1, putative | 0.0032 | 0.2612 | 0.8145 |
Plasmodium falciparum | flap endonuclease 1 | 0.0032 | 0.2612 | 0.8145 |
Leishmania major | flap endonuclease-1 (FEN-1), putative | 0.0032 | 0.2612 | 1 |
Echinococcus multilocularis | flap endonuclease GEN 1 | 0.0011 | 0.0361 | 0.1156 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (binding) | = 21 % | Antagonist activity at human adenosine A2B receptor expressed in CHO cells assessed as inhibition of NECA-stimulated cAMP level at 1 uM by scintillation counting analysis | ChEMBL. | 25063944 |
Inhibition (binding) | = 26 % | Displacement of [3H]ZM241385 from human adenosine A2A receptor expressed in CHO cells at 1 uM by scintillation counting analysis relative to control | ChEMBL. | 25063944 |
Inhibition (binding) | = 38 % | Displacement of [3H]-DPCPX from human adenosine A1 receptor expressed in CHO cells at 1 uM by scintillation counting analysis relative to control | ChEMBL. | 25063944 |
Inhibition (binding) | = 39 % | Displacement of [3H]AB-MECA from human adenosine A3 receptor expressed in CHO cells at 1 uM by scintillation counting analysis relative to control | ChEMBL. | 25063944 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.